Shannon Thyme Klinger Sells 1,418 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shannon Thyme Klinger also recently made the following trade(s):

• On Tuesday, September 3rd, Shannon Thyme Klinger sold 114 shares of Moderna stock. The shares were sold at an average price of $76.99, for a total transaction of $8,776.86.

Moderna Stock Performance

Shares of MRNA stock opened at $44.26 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The business has a fifty day moving average of $51.98 and a 200 day moving average of $90.21. The firm has a market capitalization of $17.03 billion, a price-to-earnings ratio of -7.60 and a beta of 1.69. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the business posted ($1.39) earnings per share. As a group, research analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. UBS Group dropped their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. The Goldman Sachs Group cut their price target on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Bank of America decreased their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Berenberg Bank assumed coverage on shares of Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Moderna has an average rating of “Hold” and an average price target of $83.33.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter worth $26,000. Family Firm Inc. acquired a new stake in Moderna during the 2nd quarter worth about $33,000. Bank & Trust Co purchased a new position in shares of Moderna during the 2nd quarter valued at about $36,000. Hanseatic Management Services Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at about $48,000. Finally, Plato Investment Management Ltd boosted its stake in shares of Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after buying an additional 288 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.